Novo joins venture capital firms SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners that had backed its CHF13.5m first close of the A round in November.
Delenex Therapeutics, a Switzerland-based drug developer, has extended its series A round by CHF16.7m ($19.3m) to CHF30.2m by adding Novo Ventures, the quasi-corporate venturing unit of Denmark-based medical foundation Novo, to its consortium.
Thomas Dyrberg, senior partner with Novo Ventures, will join Delenex’s board.
Novo joins venture capital firms SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners that had backed its CHF13.5m first close of the A round in November.
Fourteen months earlier, in September 2009, Delenex…
